You are not logged in.
Openly accessible

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Kalincik, Tomas, Spelman, Timothy, Trojano, Maria, Duquette, Pierre, Izquierdo, Guillermo, Grammond, Pierre, Lugaresi, Alessandra, Hupperts, Raymond, Cristiano, Edgardo, Van Pesch, Vincent, Grand'Maison, Francois, La Spitaleri, Daniele, Rio, Maria Edite, Flechter, Shlomo, Oreja-Guevara, Celia, Giuliani, Giorgio, Savino, Aldo, Amato, Maria Pia, Peterson, Thor, Fernandez-Bolanos, Ricardo, Bergamaschi, Roberto, Iuliano, Gerardo, Boz, Cavit, Lechner-Scott, Jeannette, Deri, Norma, Gray, Orla, Verheul, Freek, Fiol, Marcela, Barnett, Michael, van Munster, Erik, Santiago, Vetere, Moore, Fraser, Slee, Mark, Saladino, Maria Laura, Alroughani, Raed, Shaw, Cameron, Kasa, Krisztian, Petkovska-Boskova, Tatjana, den Braber-Moerland, Leontien, Chapman, Joab, Skromne, Eli, Herbert, Joseph, Peohlau, Dieter, Needham, Merrilee, Bacile, Elizabeth Alejandra, Oleschko Arruda, Walter, Paine, Mark, Singhal, Bhim, Vucic, Steve, Cabrera-Gomez, Jose Antonio and Butkueven, Helmut 2013, Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis, PLoS one, vol. 8, no. 5, pp. 1-9, doi: 10.1371/journal.pone.0063480.

Attached Files
Name Description MIMEType Size Downloads
shaw-persistence-2013.pdf Published version application/pdf 560.71KB 56

Title Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
Author(s) Kalincik, Tomas
Spelman, Timothy
Trojano, Maria
Duquette, Pierre
Izquierdo, Guillermo
Grammond, Pierre
Lugaresi, Alessandra
Hupperts, Raymond
Cristiano, Edgardo
Van Pesch, Vincent
Grand'Maison, Francois
La Spitaleri, Daniele
Rio, Maria Edite
Flechter, Shlomo
Oreja-Guevara, Celia
Giuliani, Giorgio
Savino, Aldo
Amato, Maria Pia
Peterson, Thor
Fernandez-Bolanos, Ricardo
Bergamaschi, Roberto
Iuliano, Gerardo
Boz, Cavit
Lechner-Scott, Jeannette
Deri, Norma
Gray, Orla
Verheul, Freek
Fiol, Marcela
Barnett, Michael
van Munster, Erik
Santiago, Vetere
Moore, Fraser
Slee, Mark
Saladino, Maria Laura
Alroughani, Raed
Shaw, Cameron
Kasa, Krisztian
Petkovska-Boskova, Tatjana
den Braber-Moerland, Leontien
Chapman, Joab
Skromne, Eli
Herbert, Joseph
Peohlau, Dieter
Needham, Merrilee
Bacile, Elizabeth Alejandra
Oleschko Arruda, Walter
Paine, Mark
Singhal, Bhim
Vucic, Steve
Cabrera-Gomez, Jose Antonio
Butkueven, Helmut
Journal name PLoS one
Volume number 8
Issue number 5
Start page 1
End page 9
Total pages 9
Publisher Public Library of Science
Place of publication San Francisco, Calif.
Publication date 2013
ISSN 1932-6203
Summary To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as “lack of efficacy” (3.3% vs. 1.7%), “scheduled stop” (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from “real-world” database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
Language eng
DOI 10.1371/journal.pone.0063480
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2013, Public Library of Science
Persistent URL http://hdl.handle.net/10536/DRO/DU:30064366

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 15 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 73 Abstract Views, 56 File Downloads  -  Detailed Statistics
Created: Fri, 13 Jun 2014, 12:06:22 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.